P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales: Lowther, D.E., Houseman, E.A., Han, G., Kleanthous, E., Knoblock, D., Zhou, X., Banerjee, S., Patel, S., Figueroa, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171634/
http://dx.doi.org/10.1097/01.HS9.0000936292.14792.3e
Descripción
Sumario:

Ejemplares similares